Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
None
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS

  • 7 views
  • 26 Nov, 2021
  • 75 locations
None
Ifosfamide and Doxorubicin Radiation Therapy and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma

RATIONALE: Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to …

combination chemotherapy
immunomodulators
kidney function tests
tumor cells
soft tissue sarcoma
  • 93 views
  • 07 Nov, 2020
  • 11 locations
None
FHD-609 in Subjects With Advanced Synovial Sarcoma

activity of FHD-609 given intravenously in subjects with advanced synovial sarcoma.

  • 0 views
  • 22 Sep, 2021
  • 8 locations
None
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma

The purpose of this study is to evaluate safety and pharmacokinetics as well as the biodistribution of OTSA101-DTPA-111In and to evaluate the safety of intravenous administration of OTSA101-DTPA-90Y.

  • 4 views
  • 22 Apr, 2021
  • 3 locations
None
Phase II Study of Regorafenib as Maintenance Therapy

Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas experiencing stable disease or response after 6 cycles of doxorubicin-based chemotherapy as 1st line chemotherapy.

  • 2 views
  • 26 Jan, 2021
  • 29 locations
None
Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas

The randomized, controlled trial is aiming at comparing local control rate between two surgical resections, barrier resection and local wide resection with 1cm or equivalent normal tissues. This is based on the fact that the goal of local surgical treatment is to remove the tumor with negative margin and best …

  • 5 views
  • 08 Nov, 2020
None
Phase III Trial of Anlotinib Catequentinib in Advanced Alveolar Soft Part Sarcoma Leiomyosarcoma Synovial Sarcoma (APROMISS)

THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA.

measurable disease
kidney function tests
angiogenesis
anthracyclines
al3818
  • 325 views
  • 01 Dec, 2021
  • 24 locations
None
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1 and

  • 28 views
  • 26 Nov, 2021
  • 39 locations
None
A Phase II Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

(Closed for enrollment): Relapsed or refractory synovial sarcoma with SS18-SSX rearrangement Cohort 3 (Closed for enrollment): Other INI1 negative tumors or any solid tumor with an EZH2 gain of

nitrosoureas
measurable disease
kidney function tests
monoclonal antibodies
small molecule
  • 2 views
  • 30 Sep, 2021
  • 25 locations
None
Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors

This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose urothelial, head and neck, gastric (stomach), esophagogastric junction (EGJ), non-small cell lung (NSCLC), esophageal or ovarian cancer that express the MAGE-A4 protein.

leukapheresis
cancer of the ovary
measurable disease
carcinoma
lung carcinoma
  • 10 views
  • 24 Nov, 2021
  • 20 locations